An update on the management of antiphospholipid syndrome

Therapeutic Advances in Musculoskeletal Disease
Mia Rodziewicz, David P D'Cruz

Abstract

Antiphospholipid syndrome (APS) is a systemic autoimmune disorder characterized by recurrent venous or arterial thrombosis with or without pregnancy morbidity in the presence of persistent antiphospholipid (aPL) autoantibodies. Anticoagulation has, until now, formed the cornerstone of treatment but a significant proportion of patients continue to experience thrombosis and pregnancy morbidity despite this treatment. Thrombosis is the most common cause of mortality and accounts for two fifths of deaths. Direct oral anticoagulant drugs represent an attractive alternative to conventional vitamin K antagonist drugs but emerging evidence suggests these may not be suitable for high-risk patients with thrombotic APS. Laboratory studies and case reports of the successful use of different classes of drugs in APS is increasing our understanding of the other pathophysiological mechanisms which may contribute to the high morbidity of APS. This review summarizes current accepted anticoagulant treatment for APS and examines other potential drugs such as immunomodulating agents, statins and novel agents such as sirolimus and defibrotide.

References

Apr 13, 1995·The New England Journal of Medicine·M A KhamashtaG R Hughes
Mar 2, 2006·JAMA : the Journal of the American Medical Association·Wendy LimJohn W Eikelboom
Dec 1, 2007·Arthritis and Rheumatism·Guillermo Ruiz-IrastorzaMunther A Khamashta
Dec 24, 2008·Annals of the Rheumatic Diseases·G Ruiz-IrastorzaM A Khamashta
May 4, 2012·Blood·Philip G de Groot, Rolf T Urbanus
Dec 12, 2013·American Journal of Reproductive Immunology : AJRI·Caroline R AlbertVikki M Abrahams
Jan 28, 2014·Annals of the Rheumatic Diseases·R CerveraUNKNOWN Euro-Phospholipid Project Group (European Forum on Antiphospholipid Antibodies)
Jul 24, 2014·The New England Journal of Medicine·Guillaume CanaudFabiola Terzi
Jan 27, 2015·Autoimmunity Reviews·Arsène MekinianUNKNOWN SNFMI and the European Forum on Antiphospholipid Antibodies
Oct 3, 2015·American Journal of Obstetrics and Gynecology·S SciasciaM J Cuadrado
Nov 15, 2015·Clinical and Applied Thrombosis/hemostasis : Official Journal of the International Academy of Clinical and Applied Thrombosis/Hemostasis·Scott C WollerC Gregory Elliott
May 11, 2016·Journal of Autoimmunity·Maria Laura BertolacciniGuillermina Girardi
Jul 28, 2016·The Journal of Clinical Investigation·Eleftheria LefkouGuillermina Girardi
Sep 19, 2016·Autoimmunity Reviews·Ignasi Rodríguez-PintóUNKNOWN CAPS Registry Project Group (European Forum on Antiphospholipid Antibodies)
Dec 4, 2016·Lupus·A YaziciD Erkan
Jul 14, 2018·Blood·Vittorio PengoAlessandra Banzato

❮ Previous
Next ❯

Methods Mentioned

BETA
ELISA
enzyme-linked immunosorbent assay
biopsy

Clinical Trials Mentioned

NCT01756508
NCT02128269

Software Mentioned

HIBISCUS
EULAR

Related Concepts

Related Feeds

Antiphospholipid Syndrome

Antiphospholipid syndrome or antiphospholipid antibody syndrome (APS or APLS), is an autoimmune, hypercoagulable state caused by the presence of antibodies directed against phospholipids.

Related Papers

Clinical Immunology : the Official Journal of the Clinical Immunology Society
Chrisanna Dobrowolski, Doruk Erkan
Current Treatment Options in Cardiovascular Medicine
Elena CucurullWendell A. Wilson
Nihon Rinshō Men'eki Gakkai kaishi = Japanese journal of clinical immunology
Tetsuya Horita
Pediatric Clinics of North America
Angelo Ravelli, Alberto Martini
© 2022 Meta ULC. All rights reserved